Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of “Moderate Buy” from Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $4.80.

Separately, HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Karyopharm Therapeutics in a report on Monday, June 3rd.

Karyopharm Therapeutics Stock Down 6.2 %

Shares of KPTI stock opened at $0.96 on Friday. The company has a market capitalization of $119.20 million, a P/E ratio of -0.75 and a beta of 0.25. Karyopharm Therapeutics has a 12-month low of $0.62 and a 12-month high of $2.14. The firm has a 50-day moving average price of $1.10 and a 200 day moving average price of $1.09.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Wednesday, May 8th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.01. The business had revenue of $33.13 million during the quarter, compared to analyst estimates of $35.02 million. As a group, research analysts expect that Karyopharm Therapeutics will post -1.25 earnings per share for the current year.

Insider Buying and Selling at Karyopharm Therapeutics

In other news, Director Deepika Pakianathan sold 360,744 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $1.00, for a total transaction of $360,744.00. Following the transaction, the director now owns 11,209 shares of the company’s stock, valued at $11,209. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last ninety days, insiders have sold 1,282,902 shares of company stock worth $1,244,993. Insiders own 4.30% of the company’s stock.

Institutional Trading of Karyopharm Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bleakley Financial Group LLC acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth approximately $33,000. Simplicity Solutions LLC acquired a new stake in Karyopharm Therapeutics during the 4th quarter worth $33,000. Wade G W & Inc. acquired a new position in shares of Karyopharm Therapeutics in the 3rd quarter valued at $60,000. SG Americas Securities LLC boosted its position in shares of Karyopharm Therapeutics by 295.0% in the 4th quarter. SG Americas Securities LLC now owns 73,430 shares of the company’s stock worth $64,000 after purchasing an additional 54,839 shares during the last quarter. Finally, Simplicity Wealth LLC bought a new position in shares of Karyopharm Therapeutics in the 1st quarter worth $66,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).